These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 20307579)

  • 1. Slow binding-tight binding interaction between benzimidazol-2-one inhibitors and HIV-1 reverse transcriptase containing the lysine 103 to asparagine mutation.
    Samuele A; Crespan E; Vitellaro S; Monforte AM; Logoteta P; Chimirri A; Maga G
    Antiviral Res; 2010 Jun; 86(3):268-75. PubMed ID: 20307579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-nucleoside HIV-1 reverse transcriptase inhibitors di-halo-indolyl aryl sulfones achieve tight binding to drug-resistant mutants by targeting the enzyme-substrate complex.
    Samuele A; Kataropoulou A; Viola M; Zanoli S; La Regina G; Piscitelli F; Silvestri R; Maga G
    Antiviral Res; 2009 Jan; 81(1):47-55. PubMed ID: 18984007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors.
    Ren J; Nichols C; Bird L; Chamberlain P; Weaver K; Short S; Stuart DI; Stammers DK
    J Mol Biol; 2001 Sep; 312(4):795-805. PubMed ID: 11575933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of interaction of novel indolylarylsulfone derivatives with K103N and Y181I mutant HIV-1 reverse transcriptase in complex with its substrates.
    Samuele A; Bisi S; Kataropoulou A; La Regina G; Piscitelli F; Gatti V; Silvestri R; Maga G
    Antivir Chem Chemother; 2011 Nov; 22(3):107-18. PubMed ID: 22095519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant.
    Ragno R; Mai A; Sbardella G; Artico M; Massa S; Musiu C; Mura M; Marturana F; Cadeddu A; La Colla P
    J Med Chem; 2004 Feb; 47(4):928-34. PubMed ID: 14761194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel 1,3-dihydro-benzimidazol-2-ones and their analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Monforte AM; Logoteta P; De Luca L; Iraci N; Ferro S; Maga G; De Clercq E; Pannecouque C; Chimirri A
    Bioorg Med Chem; 2010 Feb; 18(4):1702-10. PubMed ID: 20097079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
    Benjahad A; Croisy M; Monneret C; Bisagni E; Mabire D; Coupa S; Poncelet A; Csoka I; Guillemont J; Meyer C; Andries K; Pauwels R; de Béthune MP; Himmel DM; Das K; Arnold E; Nguyen CH; Grierson DS
    J Med Chem; 2005 Mar; 48(6):1948-64. PubMed ID: 15771439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of HIV-1 by non-nucleoside reverse transcriptase inhibitors via an induced fit mechanism-Importance of slow dissociation and relaxation rates for antiviral efficacy.
    Elinder M; Selhorst P; Vanham G; Oberg B; Vrang L; Danielson UH
    Biochem Pharmacol; 2010 Oct; 80(8):1133-40. PubMed ID: 20599774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
    Ragno R; Artico M; De Martino G; La Regina G; Coluccia A; Di Pasquali A; Silvestri R
    J Med Chem; 2005 Jan; 48(1):213-23. PubMed ID: 15634015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies.
    Ragno R; Frasca S; Manetti F; Brizzi A; Massa S
    J Med Chem; 2005 Jan; 48(1):200-12. PubMed ID: 15634014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase.
    Ren J; Stammers DK
    Virus Res; 2008 Jun; 134(1-2):157-70. PubMed ID: 18313784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3D-QSAR models on clinically relevant K103N mutant HIV-1 reverse transcriptase obtained from two strategic considerations.
    San Juan AA
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1181-94. PubMed ID: 18155520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future.
    De Clercq E
    Chem Biodivers; 2004 Jan; 1(1):44-64. PubMed ID: 17191775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.
    Fattorusso C; Gemma S; Butini S; Huleatt P; Catalanotti B; Persico M; De Angelis M; Fiorini I; Nacci V; Ramunno A; Rodriquez M; Greco G; Novellino E; Bergamini A; Marini S; Coletta M; Maga G; Spadari S; Campiani G
    J Med Chem; 2005 Nov; 48(23):7153-65. PubMed ID: 16279773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
    Mai A; Artico M; Rotili D; Tarantino D; Clotet-Codina I; Armand-Ugón M; Ragno R; Simeoni S; Sbardella G; Nawrozkij MB; Samuele A; Maga G; Esté JA
    J Med Chem; 2007 Nov; 50(22):5412-24. PubMed ID: 17910429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
    Hopkins AL; Ren J; Milton J; Hazen RJ; Chan JH; Stuart DI; Stammers DK
    J Med Chem; 2004 Nov; 47(24):5912-22. PubMed ID: 15537346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arylthiopyrrole (AThP) derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors: synthesis, structure-activity relationships, and docking studies (part 2).
    Lavecchia A; Costi R; Artico M; Miele G; Novellino E; Bergamini A; Crespan E; Maga G; Di Santo R
    ChemMedChem; 2006 Dec; 1(12):1379-90. PubMed ID: 17089434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic Study of Common Non-Nucleoside Reverse Transcriptase Inhibitor-Resistant Mutations with K103N and Y181C Substitutions.
    Lai MT; Munshi V; Lu M; Feng M; Hrin-Solt R; McKenna PM; Hazuda DJ; Miller MD
    Viruses; 2016 Sep; 8(10):. PubMed ID: 27669286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel concepts in the treatment of human immunodeficiency virus type 1 (HIV-1) infections by HIV-1-specific reverse transcriptase inhibitors.
    Balzarini J
    Verh K Acad Geneeskd Belg; 1995; 57(6):575-600. PubMed ID: 8686372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs.
    Auwerx J; Van Nieuwenhove J; Rodríguez-Barrios F; de Castro S; Velázquez S; Ceccherini-Silberstein F; De Clercq E; Camarasa MJ; Perno CF; Gago F; Balzarini J
    FEBS Lett; 2005 Apr; 579(11):2294-300. PubMed ID: 15848161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.